Basilea 和 Innoviva 合作在美国销售用于治疗 MRSA 等感染的抗生素 Zevtera。 Basilea and Innoviva partner to sell antibiotic Zevtera in the U.S. for infections like MRSA.

巴西利亚制药公司和Innoviva专用治疗公司已同意在美国商业化抗生素Zevtera (ceftobiprole),针对MRSA等感染. Basilea Pharmaceutica and Innoviva Specialty Therapeutics have agreed to commercialize the antibiotic Zevtera (ceftobiprole) in the U.S., targeting infections like MRSA. Basilea将获得400万美元的预付付款加上特许使用费。 Basilea will receive a $4 million upfront payment plus royalties. 为了满足对严重感染的有效抗生素治疗的需求,Innoviva将负责营销和分销. Innoviva will handle marketing and distribution, aiming to address the need for effective antibiotic treatments for serious infections.